Search research articles

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Home
Chinese Guidelines For Her2 Testing In Breast Cancer (2024 Edition): Summary Of Key Recommendations.

Home
Chinese Guidelines For Her2 Testing In Breast Cancer (2024 Edition): Summary Of Key Recommendations.

Related Experiment Video

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Chinese guidelines for HER2 testing in breast cancer (2024 edition): summary of key recommendations.

Yueping Liu¹, Zhiyong Liang², Hong Bu³

¹Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China yangwt2000@163.com annama@163.com liangzhiyong1220@yahoo.com hongbu@scu.edu.cn.

Journal of Clinical Pathology

|August 1, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The updated 2024 Chinese Guidelines for human epidermal growth factor receptor 2 (HER2) testing in breast cancer offer enhanced recommendations for anti-HER2 therapies. These guidelines improve accuracy and clinical relevance for better patient outcomes.

Keywords:

BREAST CANCER Evidence-Based Practice IMMUNOHISTOCHEMISTRY

More Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

Published on: December 25, 2017

Related Experiment Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

Published on: December 25, 2017

Area of Science:

Oncology
Pathology
Genetics

Background:

Human epidermal growth factor receptor 2 (HER2) is a critical biomarker in breast cancer management.
Accurate HER2 testing is essential for guiding targeted therapy selection, including emerging antibody-drug conjugates (ADCs).
Previous guidelines require updates to reflect advancements in testing methodologies and clinical applications.

Purpose of the Study:

To present the updated Chinese Guidelines for HER2 testing in breast cancer (2024 edition).
To provide comprehensive guidance on interpreting and reporting HER2 status for optimal patient stratification.
To incorporate recent advancements in HER2 testing, including AI's role and quality control measures.

Main Methods:

Revision of the 2019 guidelines by a Chinese expert panel.

Inclusion of recent scientific advancements in HER2 testing techniques.

Emphasis on enhanced quality control across specimen handling, decalcification, slide preservation, and external controls.

Main Results:

The 2024 guidelines feature significant format changes and enhanced clinical applicability.
Recommendations are strengthened with more robust evidence-based support.
Guidance is provided for identifying patients eligible for novel anti-HER2 ADC therapies.

Conclusions:

The 2024 guidelines aim to improve the accuracy and clinical relevance of HER2 testing in breast cancer.
Updates facilitate better patient selection for targeted therapies, including ADCs.
Reinforced quality control standards are expected to enhance overall testing reliability and patient care.